Abstract 1766: Effect of soy isoflavones on prostate cancer cell cycle regulation and apoptosis

Author(s):  
Peter J. Van Veldhuizen ◽  
Anup Kasi Loknath Kumar ◽  
Snigdha Banerjee ◽  
Gophal Dhar ◽  
Smita Mehta ◽  
...  
2006 ◽  
pp. 487-493
Author(s):  
Alice Hlobilková ◽  
Michaela Šváchová ◽  
Jana Knillová ◽  
Eva Pimrová ◽  
Petra Řiháková ◽  
...  

Gene ◽  
2019 ◽  
Vol 687 ◽  
pp. 261-271 ◽  
Author(s):  
Zeynep Özlem Doğan Şiğva ◽  
Tuğçe Balci Okcanoğlu ◽  
Çığır Biray Avci ◽  
Sunde Yilmaz Süslüer ◽  
Çağla Kayabaşi ◽  
...  

2003 ◽  
Vol 129 (3) ◽  
pp. 175-182 ◽  
Author(s):  
Albert A. Geldof ◽  
Marian A.B.D. Plaizier ◽  
Ilse Duivenvoorden ◽  
Marieke Ringelberg ◽  
Richard T. Versteegh ◽  
...  

2015 ◽  
Vol 11 (1) ◽  
pp. 130
Author(s):  
Nai-Xiong Peng ◽  
Chun-Xiao Liu ◽  
Xi-Sheng Wang ◽  
Ze-Jian Zhang ◽  
Su-Cai Liao

<p class="Abstract">Prostate cancer is major cause of cancer related deaths worldwide in men. There are new treatment methods and drugs are being developed with promising results in two of the prostate cancer cell lines (PPC-1 and TSU-Pr1). These two cells were treated with 20 uM of axitinib combined with dasatinib for 6-72 hours. The cell viability assessed by the cytotoxicity assay. Various regulatory genes such as c-KIT, cell cycle and apoptosis and angiogenic factors were also studied. The enzyme activity of apoptosis efector caspase-3 was colorimetrically determined. Axitinib and dasatinib combination lowered the survival rate of PPC-1 cells but enhanced the survival rate of TSU-Pr1 cells. The protein expression levels in apoptosis and angiogenesis factors were also found to be in contrast between the two cell lines. PPC-1 and TSU-Pr1 cells displayed a different response to axitinib with dasatinib, which explains different expression levels of regulators of cell-cycle, apoptosis and angiogenesis.</p><p> </p>


Sign in / Sign up

Export Citation Format

Share Document